Current Hepatitis Reports

, Volume 3, Issue 2, pp 54–60

Natural history of chronic hepatitis B

  • Alfredo Alberti
  • Giovanna Fattovich


Chronic hepatitis B virus (HBV) infection can cause chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Chronic hepatitis B is characterized by an early replicative phase with hepatitis B e antigen (HBeAg) positivity, high serum HBV-DNA levels and disease activity (HBeAgpositive chronic hepatitis), and a late inactive phase with anti-HBe seroconversion, low or undetectable serum HBV-DNA, and liver disease remission (inactive carrier state). Another form is characterized by active disease due to HBV variants not expressing HBeAg (HBeAg-negative chronic hepatitis). Both types of chronic hepatitis B can lead to cirrhosis and its complications. The incidence of cirrhosis is two to five per 100 person-years, but may be as high as eight to 10 in HBeAg-negative cases. The incidence of HCC varies geographically and increases with the duration and severity of liver disease (0.1 to 8 per 100 person-years). The prognosis is reasonably good in compensated cirrhosis, but very poor following decompensation. Viral and environmental factors influence the natural history of chronic hepatitis B and explain the heterogeneity of its clinical outcomes.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    EASL Jury: EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003, 38:533–540. The main conclusion of the most recent International Consensus Conference on the management of hepatitis B.Google Scholar
  2. 2.
    Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001, 120:1828–1853. Detailed summary of the National Institutes of Health 2000 workshop on the management of hepatitis B.PubMedGoogle Scholar
  3. 3.
    Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2001, 34:1225–1241. A comprehensive review on the different virologic and clinical aspects of chronic hepatitis B.PubMedCrossRefGoogle Scholar
  4. 4.
    Chang MH: Natural history of hepatitis B infection in children. J Gastroenterol Hepatol 2000, 15(suppl):E11-E19.CrossRefGoogle Scholar
  5. 5.
    Fattovich G: Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Bortolotti F, Jara P, Crivellaro C, et al.: Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998, 29:184–190.PubMedCrossRefGoogle Scholar
  7. 7.
    Fattovich G, Rugge M, Brollo L, et al.: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986, 6:167–172.PubMedCrossRefGoogle Scholar
  8. 8.
    Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522–1527.PubMedCrossRefGoogle Scholar
  9. 9.
    McMahon BJ, Holck P, Bulkow L, Snowball M: Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759–768. An updated review article on the clinical outcomes and prognostic markers of hepatitis B.PubMedGoogle Scholar
  10. 10.
    Yuen MF, Yuan HJ, Hui CK, et al.: A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003, 52:416–419.PubMedCrossRefGoogle Scholar
  11. 11.
    Alward WL, McMahon BJ, Hall DB, et al.: The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985, 151:604–609.PubMedGoogle Scholar
  12. 12.
    Liaw YF: Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003, 18:246–252.PubMedCrossRefGoogle Scholar
  13. 13.
    Chu CJ, Hussain M, Lok AS: Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C. Gastroenterology 2002, 122:1756–1762.PubMedCrossRefGoogle Scholar
  14. 14.
    Yuen MF, Sablon E, Yuan HJ, et al.: Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003, 37:562–567.PubMedCrossRefGoogle Scholar
  15. 15.
    Sanchez-Tapias JM, Costa J, Mas A, et al.: Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology 2002, 123:1848–1856.PubMedCrossRefGoogle Scholar
  16. 16.
    Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34:617–624.PubMedCrossRefGoogle Scholar
  17. 17.
    Funk ML, Rosenberg DM, Lok AS: World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002, 9:52–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Brunetto MR, Oliveri F, Coco B, et al.: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263–270.PubMedCrossRefGoogle Scholar
  19. 19.
    Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34:306–313.PubMedCrossRefGoogle Scholar
  20. 20.
    Perillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009–1022.CrossRefGoogle Scholar
  21. 21.
    Fattovich G, Giustina G, Sanchez-Tapias J, et al.: Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998, 93:896–900.PubMedCrossRefGoogle Scholar
  22. 22.
    Liaw YF, Sheen IS, Chen TJ, et al.: Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627–631.PubMedCrossRefGoogle Scholar
  23. 23.
    Chen YC, Sheen IS, Chu CM, Liaw YF: Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084–1089.PubMedCrossRefGoogle Scholar
  24. 24.
    Fattovich G, Brollo L, Giustina G, et al.: Natural history and prognostic factors of chronic hepatitis type B. Gut 1991, 32:294–298.PubMedGoogle Scholar
  25. 25.
    Ikeda K, Saitoh S, Suzuki Y, et al.: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J Hepatol 1998, 28:930–938.PubMedCrossRefGoogle Scholar
  26. 26.
    Fattovich G, Brollo L, Alberti A, et al.: Long-term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 1988, 8:1651–1654.PubMedCrossRefGoogle Scholar
  27. 27.
    Brunetto MR, Oliveri F, Rocca G, et al.: Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989, 10:198–202.PubMedCrossRefGoogle Scholar
  28. 28.
    Bortolotti F, Calzia R, Cadrobbi P, et al.: Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr 1986, 108:224–227.PubMedCrossRefGoogle Scholar
  29. 29.
    Realdi G, Fattovich G, Hadziyannis S, et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994, 21:656–666.PubMedCrossRefGoogle Scholar
  30. 30.
    Bosh FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271–285.Google Scholar
  31. 31.
    Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942–1956.PubMedCrossRefGoogle Scholar
  32. 32.
    Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1906–1907.CrossRefGoogle Scholar
  33. 33.
    Liaw YF, Lin DY, Chen TJ, Chu CM: Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989, 9:235–241.PubMedGoogle Scholar
  34. 34.
    Oon CJ: Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992, 31(suppl 1):S137-S142.PubMedCrossRefGoogle Scholar
  35. 35.
    Fattovich G, Pantalena M, Zagni I, et al.: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002, 97:2886–2895.PubMedCrossRefGoogle Scholar
  36. 36.
    Chung HT, Lai CL, Lok AS: Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995, 22:25–29.PubMedGoogle Scholar
  37. 37.
    Di Marco V, Lo Iacono O, Cammà C, et al.: The long-term course of chronic hepatitis B. Hepatology 1999, 30:257–264.PubMedCrossRefGoogle Scholar
  38. 38.
    De Franchis R, Meucci G, Vecchi M, et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993, 118:191–194.PubMedGoogle Scholar
  39. 39.
    Bellentani S, Dal Molin G, Miglioli L, et al.: Natural history of HBV infection: a 9 year follow-up of the Dionysos cohort. J Hepatol 2002, 36(suppl 1):228.CrossRefGoogle Scholar
  40. 40.
    De Jongh FE, Janssen HLA, De Man RA, et al.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103:1630–1635.PubMedGoogle Scholar
  41. 41.
    Fattovich G, Giustina G, Schalm SW, et al.: Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995, 21:77–82.PubMedGoogle Scholar
  42. 42.
    Liaw YF, Tai DI, Chu CM, Chen TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493–496.PubMedCrossRefGoogle Scholar
  43. 43.
    Fattovich G, Giustina G, Realdi G, et al.: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997, 26:1338–1342.PubMedCrossRefGoogle Scholar
  44. 44.
    Yang HI, Lu SN, Liaw YF, et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168–174.PubMedCrossRefGoogle Scholar
  45. 45.
    Kao JH: Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002, 17:643–650.PubMedCrossRefGoogle Scholar
  46. 46.
    Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554–559.PubMedCrossRefGoogle Scholar
  47. 47.
    Sumi H, Yokosuka O, Seki N, et al.: Influence of hepatitis B virus genotypes on the progression of chronic liver disease. Hepatology 2003, 37:19–26.PubMedCrossRefGoogle Scholar
  48. 48.
    Liaw YF: Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995, 22:1101–1108.PubMedGoogle Scholar
  49. 49.
    Fattovich G, Boscaro S, Noventa F, et al.: Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987, 155:931–935.PubMedGoogle Scholar
  50. 50.
    Rosina F, Conoscitore P, Cuppone R, et al.: Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999, 117:161–166.PubMedCrossRefGoogle Scholar
  51. 51.
    Fattovich G, Giustina G, Christensen E, et al.: Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000, 46:420–426.PubMedCrossRefGoogle Scholar
  52. 52.
    Benvegnú L, Fattovich G, Noventa F, et al.: Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994, 74:2442–2448.PubMedCrossRefGoogle Scholar
  53. 53.
    Tsai JF, Jeng JE, Ho MS, et al.: Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997, 76:968–974.PubMedGoogle Scholar
  54. 54.
    Di Martino V, Thevenot T, Colin JF, et al.: Influence of HIV infection on the response to interferon therapy and the longterm outcome of chronic hepatitis B. Gastroenterology 2002, 123:1812–1822.PubMedCrossRefGoogle Scholar
  55. 55.
    Poynard T, Mathurin P, Lai CL, et al.: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003, 38:257–265.PubMedCrossRefGoogle Scholar
  56. 56.
    Donato F, Tagger A, Gelatti U, et al.: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323–331.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Alfredo Alberti
    • 1
  • Giovanna Fattovich
    • 1
  1. 1.Department of Clinical and Experimental Medicine, Clinica Medica 5University of PadovaPadovaItaly

Personalised recommendations